Multiple Myeloma 101
The advances in multiple myeloma are forever changing and it is challenging for providers to keep up to date on the latest in diagnosis and treatment. Staying up to date on the evidence is imperative to provide best quality reports. Having knowledge shared on specific hematologic diagnosis is critical to produce high quality reports.
The research and knowledge on treating this type of cancer is quickly evolving. Our staff have limited experience with hematology oncology, and specifically with multiple myeloma. As a result of this activity, staff will have a deeper understanding of multiple myeloma in order to better review these cases. This knowledge will lessen the gap and provide for more efficient report production and quality recommendations.
AccessHope physicians, nurses, and patient navigators.
- Identify the clinical manifestations, diagnosis, and staging of multiple myeloma (MM).
- Differentiate between MGUS (monoclonal gammopathy of undetermined significance), smoldering MM, and active MM.
- Overview of MM treatment principles - frontline treatment, role of autologous stem cell transplant (ASCT), and treatment of relapsed disease.
Virtual Meeting- Zoom
Nitya Nathwani, MD Medical Director, Hematologic Malignancies, Transplantation, and Cellular Therapy, AccessHope; Associate Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
Presenter: Dr Nathwani has indicated that he does not have any relevant financial relationships.
Planner: Christina Batchelder, MSN, RN has indicated no relevant financial relationships.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer Nothing to Disclose: Patricia Aoun, MD; Chandana Banerjee, MD; Daneng Li, MD; Anna Pawlowska, MD; Michael Rosenzweig, MD; Crystal Saavedra; Behrouz Salehian, MD; Gagandeep Singh, MD; Sepidah Shayani, PharmD; Shanmuga Subbiah, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Multiple Myeloma 101 for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance